From:  How URAT1 inhibitors can shape the future of chronic gout treatment: a narrative review of uricosurics past and present

Ratio of Cmax/AUCss or Cmax/Cmin in steady-state pharmacokinetic profile for selected URAT1 inhibitors

Drug metaboliteURAT1 IC50 (nM)Cmax/AUCssCmax/CminRenal safety profile
Lesinurad [123]*7,3000.1988Serious renal issues, needed to combine with XOIs
Verinurad [124]*< 500.5233Second generation of lesinurad by AstraZeneca; failed development; needed to combine with XOIs
Dotinurad [125]*< 500.094.7Approved by the Japanese Pharmaceuticals and Medical Devices Agency; no known renal-related safety events
Benzbromarone [126]*1960.1418Used in Asia; no known renal-related safety events
6-OH benzbromarone [126]*NA0.072.83NA
Pozdeutinurad (AR882) [81, 127]*670.082.7In development; no renal safety signals identified in phase 2 trials
Return to article view

* Data have been derived from the cited publications. AUCss: area under the curve steady state; Cmax: maximum concentration; Cmin: minimum concentration; IC50: half-maximal inhibitory concentration; NA: not available; URAT1: urate transporter-1; XOI: xanthine oxidase inhibitor